ROLE OF ERADICATION THERAPY OF НELICOBACTER PYLORI IN CORRECTION OF PROTEIN-ENERGY INSUFFICIENCY IN PATIENTS ON HEMODIALYSIS

Abstract

The aim of the study. To evaluate the contribution of eradication therapy of Helicobacter pylori to the correction of protein-energy wasting (PEW) in patients on hemodialysis. Patients and methods. 102 patients with end-stage renal disease receiving chronic hemodialysis, among which 52 men and 50 women aged 49 ± 7.7 years. All patients was performed endoscopy with biopsy of antrum and body of the stomach and the determination of infection of Helicobacter pylori. The nutritional status and composition of the patient’s body was estimated using the method of a comprehensive nutritional evaluation, caliperometry, bioimpedance analysis body composition. Determining the level of acyl-ghrelin serum was performed using enzyme-linked immunosorbent assay (ELISA) using commercial kits (Spi-bio, Montignyle Bretonneux, France). All patients with a positive Hp result received 14-day three-component eradication therapy: amoxicillin 1000 mg/day, clarithromycin 500 mg/day, pantoprazole 80 mg/day. Results. In the course of the study demonstrated the deterioration of some key indicators of nutritional status based on the presence of Helicobacter pylori (HP). The level of acyl-ghrelin serum in patients with HP colonization was reduced. After the 14 days of eradication therapy of HP we saw improvements in key nutrition indicators and increase the concentration of acyl-ghrelin. Conclusion. Eradication therapy Helicobacter pylori can be considered as an additional method of PEW correction in Hp-positive hemodialysis patients.

Keywords

• protein-energy wasting
• eradication therapy
• helicobacter pylori
• hemodialysis
• acyl-ghrelin